Brief: Neurobo Pharmaceuticals Doses First Patient In The Mad Part 2 Of Its Phase 1 Clinical Trial Evaluating DA-1726 For The Treatment Of Obesity

MetaVia

26/06/2024 14:51

June 26 (Reuters) - Neurobo Pharmaceuticals Inc
 NRBO.O :
    * NEUROBO PHARMACEUTICALS DOSES FIRST PATIENT IN THE MAD
PART 2 OF
ITS PHASE 1 CLINICAL TRIAL EVALUATING DA-1726 FOR THE TREATMENT
OF OBESITY
    * NEUROBO PHARMACEUTICALS: TOP-LINE DATA READOUT FROM SINGLE
ASCENDING DOSE PART 1 EXPECTED IN Q3 2024 & FROM MULTIPLE
ASCENDING DOSE PART 2 IN Q1 2025
    * NEUROBO PHARMACEUTICALS INC: PLANNED PART 3 INTERIM DATA
READOUT
EXPECTED MID-2026 WITH TOP-LINE DATA IN SECOND HALF OF 2026

Source text for Eikon:  ID:nPn2p3q2Ta 
Further company coverage:  NRBO.O 

 ((Reuters.Briefs@thomsonreuters.com;))